Preventing Crohn's Disease Recurrence After Resection With Adalimumab: Role of Drug and Anti-Drug Antibody Levels

被引：0
|
作者：
Wright, Emily K.
Kamm, Michael A.
Selvaraj, Fabiyola
Princen, Fred
De Cruz, Peter
Hamilton, Amy L.
Ritchie, Kathryn
Krejany, Efrosinia O.
Gorelik, Alexandra
Liew, Danny
Prideaux, Lani
Lawrance, Ian C.
Andrews, Jane M.
Bampton, Peter A.
Jakobovits, Simon
Florin, Tim
Gibson, Peter R.
Debinski, Henry
Gearry, Richard B.
Macrae, Finlay A.
Samuel, Douglas
Kronborg, Ian
Radford-Smith, Graham L.
Selby, Warwick
Johnston, Michael J.
Woods, Rodney
Elliott, Peter R.
Bell, Sally
Brown, Steven J.
Connell, William
Desmond, Paul V.
Singh, Sharat
机构：
来源：
GASTROENTEROLOGY | 2015年 / 148卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Tu1289
引用
收藏
页码：S849 / S849
页数：1
相关论文
共 50 条
  • [41] UTILITY OF MEASURING ADALIMUMAB DRUG LEVELS AND ANTI-DRUG ANTIBODIES IN CLINICAL PRACTICE: A LARGE IBD REFERRAL CENTRE EXPERIENCE
    Warner, B. D.
    Johnston, E. L.
    Digby-Bell, J. L.
    Unsworth, N.
    Anderson, S.
    Sanderson, J. D.
    Arkir, Z.
    Irving, P. M.
    GUT, 2015, 64 : A93 - A93
  • [42] DIFFERENCES IN SERUM DRUG LEVELS AND ANTI-DRUG ANTIBODIES IN PATIENTS WITH INFLAMMATORY ARTHRITIS TREATED WITH ORIGINATOR VS BIOSIMILAR ADALIMUMAB
    Jyssum, I.
    Gehin, J. E.
    Kristianslund, E.
    Sexton, J.
    Worren, D.
    Hu, Y.
    Kvien, T. K.
    Haavardsholm, E. A.
    Bolstad, N.
    Syversen, S. W.
    Goll, G. L.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 362 - 363
  • [43] Clinical Utility of Measuring Infliximab (IFX) and Adalimumab (ADA) and Anti-drug Antibody Levels Using the LabCorp Assay in Patients With Inflammatory Bowel Disease (IBD)
    Brown, Sara
    Perinbasekar, Rajiv
    Syed, Nauroz
    Lonsako, Shumet
    Cross, Raymond
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S406 - S406
  • [44] PROACTIVE MONITORING OF INFLIXIMAB (IFX) AND ADALIMUMAB (ADA) DRUG AND ANTI-DRUG ANTIBODY CONCENTRATION UTILIZING THE LABCORP ASSAY IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS
    Perinbasekar, Rajiv A.
    Brown, Sara A.
    Syed, Nauroz
    Lonsako, Shumet
    Cross, Raymond K.
    GASTROENTEROLOGY, 2017, 152 (05) : S392 - S392
  • [45] THE PRESENCE OF TOTAL ANTI-DRUG ANTIBODIES TO BIOLOGIC DRUGS DOES NOT ADVERSELY AFFECT LONG-TERM OUTCOMES IN CROHN'S DISEASE PATIENTS WITH ADEQUATE DRUGS LEVELS AND ABSENT FREE ANTI-DRUG ANTIBODIES
    Samaan, M. A.
    Unsworth, N.
    Ward, M.
    Warner, B.
    Sanderson, J. D.
    Arkir, Z.
    Irving, P. M.
    GUT, 2016, 65 : A255 - A256
  • [46] Clinical Characteristics of Patients with Juvenile Idiopathic Arthritis Who Undergo Adalimumab Drug Level Testing and Anti-Drug Antibody Assessment
    Vallejos, Chelsea
    Cooper, Jennifer
    Pan, Ingrid
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 705 - 707
  • [47] NONBIOLOGIC DRUG USE BEFORE AND AFTER INITIATION OF USTEKINUMAB OR ADALIMUMAB FOR CROHN'S DISEASE PATIENTS
    Obando, Camilo
    Ding, Zhijie
    Muser, Erik
    Slaton, Terra
    Kozma, Chris
    GASTROENTEROLOGY, 2019, 156 (06) : S882 - S882
  • [48] Proactive Therapeutic Drug Monitoring of Adalimumab in Patients With Crohn's Disease
    Papamichael, Konstantinos
    Dubinsky, Marla C.
    Cheifetz, Adam S.
    GASTROENTEROLOGY, 2023, 164 (01) : 164 - 165
  • [49] Evaluation of the Homogenous Mobility Shift Assay for Infliximab and Adalimumab Anti-drug Antibody Detection in the Clinical Laboratory
    Keating, Paula Elizabeth
    Hock, Barry D.
    Chin, Paul K. L.
    O'Donnell, John Liston
    Barclay, Murray Lindsay
    THERAPEUTIC DRUG MONITORING, 2024, 46 (05) : 619 - 626
  • [50] Drug choice in preventing postoperative Crohn's disease - Reply
    McLeod, RS
    GASTROENTEROLOGY, 1996, 110 (02) : 652 - 653
12345